Navigation Links
Anadys Highlights ANA773 Data to be Presented at ASCO
Date:5/25/2011

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company focused on developing medicines for the treatment of hepatitis C, announced today that it will present data from a previously conducted cancer study of ANA773, the Company's oral immuno-modulator that acts via the TLR-7 pathway, at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.  The data from the completed Phase I study is being presented on June 4, 2011 in a poster titled "Phase I Open Label, Dose Escalation Study of ANA773 Tosylate, an Oral Prodrug of a Toll-Like Receptor-7 Agonist, in Patients with Advanced Solid Tumors".  The poster will be available on the Company's website at www.anadyspharma.com as of the date of presentation.  

In the Phase I cancer study, ANA773 showed a favorable safety and tolerability profile at doses that had desired effects on the innate immune system.  A confirmed partial response was achieved in a patient with melanoma and prolonged stable disease was observed in additional patients.  A maximum tolerated dose (MTD) was not reached in this study.  These results suggest that ANA773 may provide clinical benefit to cancer patients.  

"The clinical activity seen with ANA773 in this Phase I oncology study is quite promising," said James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer.  "While Anadys is focusing its development efforts in the area of hepatitis C, we continue to believe that ANA773 holds promise for the treatment of a range of cancer types, particularly in combination with other agents such as monoclonal antibodies that rely on immune mechanisms for activity."  

About the Concluded Phase I study of ANA773 in Cancer

Patients with
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
3. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
5. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
9. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
10. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  Continuing its long ... infarction (MI), Beckman Coulter , Inc. announces the ... its new Access AccuTnI+3 troponin I assay for use ... "Clinicians have depended on Beckman Coulter,s troponin ... AccuTnI+3 assay has the proven performance to continue providing ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Bayer CropScience ... first Bayer Bee Care Community Leadership Award. The award ... Congressional Reception in Washington, D.C., an event where ... to the world’s food supply. , The Bayer ... harnessed the power of the honey bee colony to ...
(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... with financial software provider BlackLine Systems  and enterprise ... SAP ) for a webinar next week entitled "No ... from BlackLine and SAP to Help Keep Its Account Reconciliations ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at finance, ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
Breaking Biology Technology:Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 2Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 3Community Mentor Wins Inaugural Bayer CropScience Bee Care Leadership Award 4Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2
... Former AstraZeneca Exec to Lead Hong Kong-based subsidiary Pangu ... held biopharmaceutical company focused on discovery and development of ... for multiple disease indications, today announced that Dr. James ... of Clinical Development at aTyr Pharma and President of ...
... One Corporation (Pink Sheets: MNCN), announced today that its ... serve as the company,s Chief Financial Officer, effective March ... said, "Pat brings a strong background in finance to ... financial expertise will be great assets to Mach One ...
... Alternext US: CVM) announced today that it is ... allow drugs developed using stem cells and other biological ... their shelf life. The availability of this new ... time to market by eliminating complicated and time consuming ...
Cached Biology Technology:Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 2Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 3Mach One Announces Appointment of Chief Financial Officer 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4
(Date:6/19/2013)... for human consumption qualifies as a gluten-free cereal that ... scientists have confirmed in a study published in ACS, ... , Joyce Irene Boye and colleagues point out that ... alone have CD. They develop gastrointestinal and other symptoms ... contain gluten-related proteins. Boye,s team sought to expand dietary ...
(Date:6/19/2013)... fall 2012, the European Medicines Agency (EMA) approved ... first ever gene therapy for clinical use in ... had developed AAV-LPL S447X for the treatment of ... deficiency (LPLD) which affects approximately one or two ... severe, life-threatening inflammations of the pancreas. Afflicted individuals ...
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2
... its eruption in early June, several NASA satellites have captured ... Chilean Volcano called Puyehue-Cordn Caulle and have tracked it around ... FLICKR image gallery that shows the progression of the plume ... Complex includes the Puyehue volcano, the Cordn Caulle rift zone ...
... June 15, 2011 A first of its kind ... Energy,s Oak Ridge National Laboratory is providing a close-up ... Lignin, a major component of plant cell walls, aggregates ... of cellulosic ethanol. The exact shape and structure of ...
... that add up over time could create an evolutionary express ... researchers from the University of Pittsburgh and the University of ... the Proceedings of the National Academy of Sciences ... known as transcriptional enhancerswhich determine the when, where, and how ...
Cached Biology News:NASA satellite gallery shows Chilean volcano plume moving around the world 2NASA satellite gallery shows Chilean volcano plume moving around the world 3ORNL neutrons, simulations reveal details of bioenergy barrier 2Leaky genes put evolution on the fast track, Pitt and UW-Madison researchers find 2
Spastin (Sp 3G11/1)...
... MaV203 Competent Yeast Cells are designed for ... 1). S. cerevisiae strain MaV203 contains deletions ... for use with GAL4-based two-hybrid systems. The ... for selection of ProQuest bait and prey ...
...
Recombinant Rhesus Macaque IFN-alpha...
Biology Products: